ABL001 (Asciminib): Selectivity & Specificity

ABL001 (Asciminib) is a potent inhibitor of CYP1A2 (20880 nM), CYP2A6 (87180 nM), CYP2C19 (38000 nM), CYP2E1 (758000 nM), UGT1A1 (560 nM), ABL1 (31 nM), ABL1 T315I (148 nM), BCR-ABL1 (0.61 nM), BCR-ABL1 T315I (7.64 nM), CDK2 (27000 nM), 5-lipoxygenase (3300 nM), VMAT-2 (3500 nM), 5HT2B (5100 nM), Ad3 (21000 nM), 5HT2A (18000 nM), NET (22000 nM), hERG (11400 nM), ABL1 M351T (47 nM), ABL1 F359V (6066 nM), ABL1 E255K (10 nM), ABL1 Y253H (28 nM), ABL1 E255V (24 nM), ABL1 M244V (5223 nM), ABL1 F317L (6 nM), ABL1 F311I (107 nM), ABL1 V299L (562 nM), ABL1 T315I/E255V (93 nM), ABL1 T315I/F359V (6631 nM), ABL1 T315I/G250E (7451 nM), ABL1 T315I/E255K (8944 nM), ABL1 T315I/E453K (2931 nM), ABL1 T315I/M351T (>10000 nM), ABL1 T315I/F311I (7061 nM), ABL1 T315I/H396R (>10000 nM), ABL1 T315I/Y253H (6981 nM), ABL1 T315I/F317L (860 nM), ABL1 T315M (996 nM), ABL1 G250E/V299L (2601 nM), ABL1 F317L/F359V (5214 nM), ABL1 Y253H/E255V (5014 nM), ABL1 T253H/F359V (>10000 nM). ABL001 (Asciminib) exhibits the greatest inhibitory potency toward BCR-ABL1 (IC50 = 0.61 nM).